| Overview |
| bs-3589R-FITC |
| eNOS (Thr113) Polyclonal Antibody, FITC Conjugated |
| WB, FCM, IF(IHC-P), IF(IHC-F), IF(ICC) |
| This phosphorylation site is homologous across the listed species; this phosphorylation site does not exist in human due to a Thr-Ser substitution. |
| Human, Rat |
| Mouse, Dog, Rabbit |
| Specifications |
| FITC |
| Rabbit |
| KLH conjugated synthetic phosphopeptide derived from mouse eNOS around the phosphorylation site of Ser113 |
| Thr113 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 18127 |
| P70313 |
| Cytoplasm, Cell membrane |
| eNOS; Nos-3; ecNOS; 2310065A03Rik; Nitric oxide synthase, endothelial; Constitutive NOS; cNOS; EC-NOS; Endothelial NOS; NOS type III; NOSIII; Nos3 |
| Produces nitric oxide (NO) which is implicated in vascular smooth muscle relaxation through a cGMP-mediated signal transduction pathway. NO mediates vascular endothelial growth factor (VEGF)-induced angiogenesis in coronary vessels and promotes blood clotting through the activation of platelets. May play a significant role in normal and abnormal limb development. |
| Application Dilution |
| WB |
1:300-5000 |
| FCM |
1:20-100 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz